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Cause for Concern?*Mark Dayer, BSC, MBBS, PHD,y Martin Thornhill, MBBS, BDS, MSC, PHDzI n 1923, Lewis and Grant (1) were the ﬁrst to sug-gest that bacteria released into the circulation asa consequence of a dental procedure might cause
infective endocarditis (IE). In 1955, the American
Heart Association (AHA) published the ﬁrst guide-
lines that recommended antibiotic prophylaxis to
reduce the risk of IE following invasive procedures
(2). Since that time, there has been a gradual reduc-
tion in the intensity and duration of antibiotic pro-
phylaxis, and the number of patients for whom it is
recommended has been reduced.
In April 2007, the latest iteration of the AHA
guidelines (3) provided an update on the previous
guidelines from 1997 (4). The authors of the most
recent guidelines felt that the beneﬁts of antibiotic
prophylaxis were likely to be small, and that only
patients at the highest risk of an adverse outcome
should be offered prophylaxis for invasive dental
procedures. Prophylaxis for those at moderate risk
of an adverse outcome, and/or for those having geni-
tourinary or gastrointestinal tract procedures was no
longer recommended. In the ﬁnal paragraph of the
document, the AHA urged that studies to document
the impact be instituted promptly, “so that any change
in incidencemay be detected sooner rather than later.”
Since 2007, a number of studies have been pub-
lished that have examined the impact of the AHA
guidelines. Rogers et al. (5), who reported on their
experience in a San Francisco medical center in 2008,*Editorials published in the Journal of the American College of Cardiology
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paper to disclose.demonstrated no increase in the number of admissions
9 months after the guideline change. A study by Bor
et al. (6), which used National Inpatient Sample Data to
assess a broad sample of patients from 1998 to 2009,
did not show any inﬂection in the rise of IE after the
guideline change, nor was there an increase in the
number of cases secondary to streptococcal infections;
however, these investigators only looked out to 2 years
after the change. DeSimone et al. (7), who looked at
data from the start of 1999 to the end of 2010, used very
detailed data from the Rochester Epidemiology Proj-
ect. They concluded that there was no perceivable in-
crease in the incidence of viridans group streptococci
(VGS) in their sample; however, the small sample size
must be considered. There were only 3 documented
cases of VGS-IE in their sample between 2007 and 2010.
Pasquali et al. (8), who looked speciﬁcally at IE in
children in 37 hospitals between 2003 and 2010, found
no signiﬁcant change in the absolute numbers of cases
before and after the guideline change. Finally, Bikdeli
et al. (9) looked at admissions of patients older than 65
years by using Medicare inpatient Standard Analytic
Files. They recorded a reduction in the absolute
numbers, but no correction was made for the absolute
numbers of patients enrolled in Medicare eligible for
treatment. They commented, “our analysis, however,
was not meant to be a comparative effectiveness study
to prove the non-inferiority of more restrictive use of
antibiotics for endocarditis prophylaxis.”SEE PAGE 2070The latest study to look at the impact of the 2007
guidelines is published in this issue of the Journal (10). The
data were extracted from the National Inpatient Sample, as
in the Bor et al. study (6). The investigators examined the
data between 2000 and 2011, extending the follow-up time
after thechange inguidelines to4years.Thedataconﬁrmed
a steady rise in thenumberof cases of IE. Importantly, there
was no acceleration in this rise, unlike in the United
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2078Kingdom (11). The reasons for the rise are, almost certainly,
multifactorial. They probably reﬂect a lowered diagnostic
threshold, an aging population, and an increase in the
number of procedures that can predispose patients to the
developmentof IE.Theremight alsobesomeartefact in this
rise, because of changes in hospital coding practice, with
double (or more) counting of patients, because of transfer
between hospitals, or because patients are discharged and
brought back on a daily basis for outpatient-based antimi-
crobial therapy. In the aforementioned Rochester Epide-
miology Project, the incidence of IE decreased (7).
As in the Bor et al. (6) study, the investigators
attempted to look at the microbiology of IE. This was
difﬁcult for 2 reasons: 1) because the proportions of
patients coded as having a causative organism changed
over time; and 2) the organism coded was not neces-
sarily the organism that caused IE. Nonetheless, what
is disconcerting is that the number of streptococcal
cases appears to be rising signiﬁcantly, raising the
possibility that the change in guidelines has resulted in
an increase in the number of streptococcal cases.
Examining a longer time frame is potentially
important. In the United Kingdom, in March 2008, the
National Institute for Health and Care Excellence
recommended that antibiotic prophylaxis should no
longer be used for anyone. Dental protection societies
rapidly withdrew insurance coverage for reactions to
prophylactic antibiotics, and there was a dramatic fall
in their prescription. In 2011, we published a study
looking at 2 years of follow-up, and we found no
difference in the incidence of IE (12). However, a
subsequent study that looked at 5 years after theguideline change demonstrated a signiﬁcant increase
in the number of cases above the baseline trend (12).
The problems with the trials that enroll large
numbers of patients and that rely on coding data are
that there are likely to be inaccuracies in the database,
which may affect the results, although the numbers,
and hopefully, the lack of systematic bias, minimizes
this effect. There are data to suggest that the coding of
IE in similar databases is quite accurate (13). Also, there
is no estimation in the paper of the impact of the 2007
AHA guidelines on the prescribing of antibiotic pro-
phylaxis. It remains unclear how practice has changed,
if at all, and who continues to get antibiotic prophylaxis,
although there is a suggestion that there has been some
shift, at least among dentists (14). Furthermore, corre-
lation does not equal causation, and there is no proof
that the effect seen is the result of the guideline change.
This is an important study that raises important
questions about the impact of the AHA guidelines and
underlines the need for ongoing monitoring of both
antibiotic prophylaxis prescribing practices and the
incidence of IE. However, as the investigators point
out, the fundamental problem is that there has never
been a randomized controlled clinical trial into the
efﬁcacy of antibiotic prophylaxis, and so there is no
reliable evidence to support its use. The time for this
to change is long overdue.
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